Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China-Reference-Cited by-同舟云学术

Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China

Published:2012-04-23 Issue:3 Volume:8 Page:232-243
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:

Author:

WU Yi-Long,CHU Da-Tong,HAN Baohui,LIU Xuyi,ZHANG Li,ZHOU Caicum,LIAO Meilin,MOK Tony,JIANG Haiyi,DUFFIELD Emma,FUKUOKA Masahiro

Publisher

Wiley

Subject

Oncology,General Medicine

Reference33 articles.

1. Major causes of death among men and women in China;He;N Engl J Med,2005

2. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up;D'Addario;Ann Oncol,2008

3. Cancer statistics;Jemal;CA Cancer J Clin,2009

4. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial;Kim;Lancet,2008

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy;Vaccines;2024-05-05

2. The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports;Frontiers in Oncology;2023-09-19

3. Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present);Pharmaceuticals;2023-04-03

4. The Role of Tyrosine Kinase Inhibitors in Reduction of Mortality from Non-small Cell Lung Cancer: A Meta-analysis;Combinatorial Chemistry & High Throughput Screening;2023-04

5. Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer;Cancers;2023-03-14